

Report to:	Private Trust Board	Agenda item:	6
Date of Meeting:	29 April 2020		

Title of Report:	Finance Board Report	
Status:	Approval	
Board Sponsor:	Simon Wade, Interim Director of Finance	
Author:	Sarah Wisher-Davies, Interim Head of Financial Management	
Appendices	Appendix 1	Control Total Performance
	Appendix 2	Activity Performance
	Appendix 3	Income Performance
	Appendix 4	QIPP Performance
	Appendix 5	Capital Expenditure
	Appendix 6	Statement of Financial Position
	Appendix 7	Cash
	Appendix 8	Single Oversight Framework
	Appendix 9	STP 2019/20 Financial Performance

## 1. Executive Summary of the Report

The purpose of this report is to set out the Trust's financial performance at the end of the 2019/20 financial year.

At the start of the 2019/20 financial year, the Trust was set a control total of a £7.83 million surplus with access to a further £5.82 million of Provider Sustainability Funding (PSF) if this was achieved, taking the potential surplus to £13.65 million. To deliver this level of surplus, savings of £12.90 million were planned through the Quality, Innovation, Productivity and Prevention (QIPP) programme. The Trust delivered a year end position which is £9.82 million away from the control total. The consequence of not achieving its control total has resulted in the loss of £3.78 million of possible Provider Sustainability Funding during Quarters 3 and 4.

As illustrated in Appendix 1 the full year position at the end of the year for the Trust is a surplus of £52,000 which is £13.60 million below plan including £3.78 million of lost Provider Sustainability Funding. QIPP savings of £10.76 million have been delivered which is £2.15 million lower than planned levels.

NHSI/E have confirmed the revenue impact arising from the preparation and management of the COVID-19 pandemic during March will be reimbursed. £1.02 million will be paid to cover revenue costs including PPE, backfill staff costs to cover COVID-19 sickness and self-isolation, as well as lost income from car parking and catering.

## 2. Recommendations (Note, Approve, Discuss)

The Board should note the financial position at the end of the 2019/20 financial year.

**Action: All**

<b>3.</b>	<b>Legal / Regulatory Implications</b>
	Not achieving financial duties will impact on the ability for the Trust to secure the economy, efficiency and effectiveness in its use of resources.
<b>4.</b>	<b>Risk (Threats or opportunities, link to a risk on the Risk Register, Board Assurance Framework etc)</b>
	In line with the Risk Assessment Framework : The Trust fails to deliver its financial plan which leads to the Trust having a Single Oversight Framework rating of three or higher, representing a material level of financial risk. This results in a lack of confidence from the Trust's commissioners and the regulator and increases the level of scrutiny which utilises significant resources and can damage the reputation of the Trust. Failure to deliver the financial plan results in a loss of national Provider Sustainability Funding (PSF) which we are dependent upon for the Trust's Estate Redevelopment Programme.
<b>5.</b>	<b>Resources Implications (Financial / staffing)</b>
	Not Applicable
<b>6.</b>	<b>Equality and Diversity</b>
	Not Applicable
<b>7.</b>	<b>References to previous reports</b>
	Standing Item
<b>8.</b>	<b>Freedom of Information</b>
	Private

## **Finance Report for the 12 Month Period Ending the 31 March 2020**

### **1.0 Executive Summary**

For the financial year 2019/20, the Trust has been set a control total of a £7.83 million surplus with access to a further £5.82 million of Provider Sustainability Funding (PSF) if this is achieved, taking the potential surplus to £13.65 million. To deliver this level of surplus, savings of £12.90 million were planned through the Quality, Innovation, Productivity and Prevention (QIPP) programme. The Trust delivered a year end position which is £9.82 million away from the control total. The consequence of the Trust not achieving its control total has resulted in the loss of £3.78 million of possible Provider Sustainability Funding.

As illustrated in Appendix 1 the full year position at the end of Month 12 for the Trust is a surplus of £52,000 which is £13.60 million below plan including £3.78 million of lost Provider Sustainability Funding for Quarter 3 and 4. QIPP savings of £10.76 million have been delivered which is £2.15 million lower than planned levels.

The revenue impact arising from the preparation and management of the COVID-19 pandemic will be reimbursed. £1.02 million will be paid to cover revenue costs including PPE, backfill staff costs to cover COVID-19 sickness and self-isolation, as well as lost income from car parking and catering. Income lost through the change in activity has been addressed through the STP.

Against the Single Oversight Framework the Trust has a rating of '3' at Month 12, this is below plan and further detail is provided in Appendix 8.

### **2.0 Key Financial Indicators**

The key financial indicators for the year to date are illustrated in the table below:

	<b>2019/20 Year End Summary</b>		
	<b>YTD Plan £000's</b>	<b>YTD Actual £000's</b>	<b>YTD Variance £000's</b>
Single oversight financial score	1	3	-
Net Surplus/ (Loss)	1,529	(8,289)	(9,818)
Surplus/(Loss) on a control total basis	13,652	52	(13,600)
Elective Income performance	18,164	17,506	(658)
Pay costs	(221,493)	(235,984)	(14,491)
Non Pay costs (excl. high cost drugs)	(72,569)	(82,056)	(9,487)
QIPP target against delivery	12,901	10,756	(2,145)
Agency staff utilisation	(4,542)	(7,276)	(2,734)
Cash balance	13,154	13,505	351
Capital Expenditure	34,552	27,985	(6,566)

### 3.0 Activity and Income

Contract income was £1.91 million under plan for the financial year 2019/20. Excluding High Cost Drugs (which are a pass through payment), contract income was £850,000 below plan. Income was affected during March, in all points of delivery, due to the changes required to prepare for the COVID-19 response. The overall position was sustained in line with forecast assumptions, due to year end agreements already in place with key commissioners and a benefit in the movement in Partially Completed Spells.

Operating income is £13.46 million above plan, excluding PSF, which is mainly due to a £9.38 million income adjustment required to reflect the centrally funded increase in employer NHS pension contributions from April 2019. The Trust was only informed of the full implications and impact of this central adjustment during March. The positive variance against plan is £3.64 million, excluding the pension adjustment and PSF. This is due to higher than planned central income, offset by catering and car parking income being below plan, significantly so for Month 12 due to the impact of COVID-19.

As the Trust was below its control total plan for Quarter 3 and 4, no PSF has been achieved since September.

### 4.0 Expenditure

At the end of Month 12 pay costs were £14.49 million higher than planned levels. This position includes the £9.38 million adjustment to account for the centrally funded employers pensions contribution increase from April 2019, informed during March. Excluding the pension adjustment, pay was £5.11 million over plan by the end of the year, this was a further increase on the Month 11 adverse position, with increases in both agency and substantive staff expenditure.

All divisions are overspent on pay at Month 12. The Surgical Division saw further high levels of expenditure on agency. The Medicine Division pay costs have continued to be high, particularly around agency costs and Health Care Assistants. In the Estates & Facilities Division the level of spend has stabilised over recent months and whilst it is still above plan, expenditure levels have dropped from the levels earlier in the year.

Agency spend for the year was £7.28 million, which is significantly above plan and above the NHS England / Improvement Agency Ceiling, thus triggering a '3' on their risk rating for agency spend, which impacts on the Single Oversight Framework rating for the Trust. The increase is reflective of the national position in relation to Agency staffing.

Non-pay expenditure was £9.49 million higher than plan, excluding High Cost Drugs, due predominately to planned QIPP schemes not being delivered in line with plan and the level of spend on medical and surgical consumables. QIPP was delivered through non-recurrent vacancies and other one off items rather than planned schemes that will deliver recurrent benefits to the Trust and improve financial sustainability.

Author : Sarah Wisher-Davies, Interim Head of Financial Management Document Approved by: Simon Wade, Interim Director of Finance	Date: April 2020 Version:
Agenda Item:	Page 4 of 8

## 5.0 Divisional Performance

The performance by individual division is summarised below:

- **Medicine** - £7.79 million adverse variance at Month 12.
  - Pay was £2.84 million overspent of which agency nursing was £2.21 million for the year, offsetting vacancies in substantive roles. High Healthcare Assistant bank spend has continued throughout the year.
  - Non-delivery of QIPP within non-pay is the significant driver of the adverse expenditure position.
  - The Division is £981,000 under plan for Contract Income, driven by an under-recovery of High Cost Drugs and day case performance. Non-Elective activity fell in Month 12, due to COVID-19.
- **Surgery** – £1.25 million adverse variance at Month 12.
  - Pay expenditure was £847,000 below plan for the year. There are underspends across a number of pay groups and particularly within Medical staff and Scientific and Professional staff.
  - Contract Income is £550,000 below plan for the year. In Month 12 there was a significant impact on elective activity as the Trust prepared for COVID-19.
  - Non-pay spend was £1.55 million above plan year to date, with a £393,000 decrease in month, this was as a result of QIPP plans set against non-pay but delivered elsewhere.
- **Women and Children** - £12,000 adverse variance at Month 12
  - Pay was overspent in month due to additional costs in maternity. There continue to be underspends as a result of vacancies, predominately within Pharmacy and NICU, which contribute to a positive variance of £532,000.
  - Month 12 non-pay is £220,000 adverse to plan in month, and £535,000 adverse at year end. The Month 12 position is due to increased drug costs and medical and surgical consumables spend. Also included is £60,000 IT system costs which have been reimbursed through an external source.
  - Income is £97,000 favourable to plan at Month 12. This includes the £60,000 detailed above.
- **Estates & Facilities** - £952,000 adverse variance at Month 12
  - Income was £663,000 below plan for the year, mainly driven by Car Parking Income below planned levels and the recent impact of COVID-19.
  - Pay was £421,000 above plan due to domestic bank spends and over spending within Portering. Following recovery measures Portering costs are running within budget but they ended the year £100,000 above plan.
  - Non-pay was £132,000 positive to plan year to date mainly due to the one-off benefit from the CHP settlement received in Month 5.

- **Corporate** - £192,000 adverse variance at Month 12
  - The adjustment to account for the centrally funded pension changes were made within Finance and increase both pay and income variances by £9.38 million.
  - Pay includes £208,000 relating to COVID-19 costs, whilst other corporate areas underspent due to vacancies.
  - The position includes central assumptions around income due from pay awards, winter funding, and income related to COVID-19. The impact of elements of commissioner funding and reimbursements are included within the Corporate Division.
  - Non pay expenditure included £408,000 of COVID-19 costs for March.

## 6.0 QIPP

Efficiency savings of £12.90 million were required to be delivered through the QIPP programme. For the financial year £10.76 million savings have been delivered, which was 83% of the plan set; the percentage delivered against plan in month reduced to 58% in March. The gap between plan and actual delivery in 2019/20 was £2.14 million.

The shortfall in the QIPP position was a significant block to the delivery of the original financial plan for 2019/20. Recurrent savings were not delivered at the required levels which will have a significant knock on effect to the financial plan for 2020/21 and will restrict any potential for investment within financial plans.

The QIPP outcome for the year 2019/20 is shown in Appendix 4.

## 7.0 Outturn Position

Following the reforecast of the financial position in December 2019 the Trust was required to deliver an overall surplus of £3.31 million which was an adverse variance to plan of £10.34 million. However with the deterioration in the financial position during Month 10 and Month 11, it was agreed with NHSE/I that the Trust would deliver an overall surplus of £128,000 which is an adverse variance of £13.52 million.

The outturn position for the Trust, prior to central adjustments is a surplus of £137,000, a slight improvement on the forecast at Month 11. In addition to this there has been recognition by NHSE/I that the impact of COVID-19 will result in annual leave due to be taken by staff being carried forward. The Trust has been able to recognise the impact of this and this has resulted in a reported surplus position of £52,000.

## 8.0 Capital

Overall expenditure for 2019/20 is £6.57 million behind plan. This is primarily driven by delays in the ward upgrade programme and the Estates Redevelopment programme, as well as slippage on IM&T and Medical equipment.

As in previous months, the position reflects cost pressures in a number of projects, including the Therapies build, SSD upgrade, and the OMFS relocation.

The overall capital position is in line with last month's forecast outturn. However, the forecast did not include £1.08 million spend on COVID-19 related schemes, including works to wards and equipment. Other projects have slipped due to this new focus, including IT spend, backlog maintenance and slippages in RUH North demolition and decant works.

A further analysis of the capital position can be found in Appendix 5.

## 9.0 Statement of Financial Position

At Month 12 the value of non-current assets, which are the buildings and equipment within the Trust, are £11.38 million below the planned level. In line with good practice, the Trust commissioned a full valuation of non-current assets as at 31 March 2020. The review contributed to a net impairment of £9.70 million due to the change in building values. There has been a level of capital slippage.

Inventories were £1.25 million higher than plan, due in part to the scope of inventory capture resulting from the implementation of the Inventory Management System during the year.

There is a variance on receivables of £9.11 million, this is primarily due to non-achievement of PSF in 2019/20 and commissioner income being behind plan.

PDC is £421,000 above planned levels. This is due to the impact of £1.70 million planned PDC funding for the Local Healthcare Records project not being drawn down, offsetting additional PDC funding for various IT projects.

The full Statement of Financial Position is shown in Appendix 6.

## 10.0 Cash

The cash balance at the end of Month 12 was £13.5 million. This is £4.5 million lower than forecast. The balance reflects the slippage in the capital programme and bonus PSF of £7.7 million from 2018/19 which has been offset by the deteriorating Income and Expenditure position and non-achievement of 2019/20 PSF in the latter half of the financial year.

The cash position is shown in Appendix 7.

## 11.0 Summary and recommendations

The position at the end of the financial year shows a surplus in line with the agreed outturn with NHSE/I.

The Board of Directors are asked to note the financial position of an overall surplus of £52,000 as at the end of the 2019/20 financial year. The position is in line with what has been discussed and agreed with NHS England / Improvement and is now subject to audit.

# Finance Report

## APPENDIX 1 - CONTROL TOTAL PERFORMANCE






	Year to date		
	<u>Plan £'000</u>	<u>Actual £'000</u>	<u>Variance £'000</u>
Contract Income	313,894	311,984	(1,910)
Operating Income	38,465	51,423	12,958
Pay	(221,493)	(235,984)	(14,491)
Non Pay	(72,569)	(82,056)	(9,487)
High Cost Drugs and Devices	(35,950)	(34,933)	1,017
<b>EBITDA</b>	<b>22,347</b>	<b>10,434</b>	<b>(11,913)</b>
Interest payable/receivable	(180)	(84)	96
Depreciation	(12,599)	(12,263)	336
PDC	(6,334)	(5,856)	478
Other Finance Charges	(2,752)	(9,700)	(6,948)
<b>Net Surplus/(Deficit)</b>	<b>481</b>	<b>(17,469)</b>	<b>(17,950)</b>
Donated Asset income	(2,525)	(1,278)	1,247
Donated Asset depreciation	821	758	(62)
Impairment	2,752	9,703	6,951
Gain / loss on disposal of an asset	0	(3)	(3)
<b>Control total (excl PSF/MRET )</b>	<b>1,529</b>	<b>(8,289)</b>	<b>(9,818)</b>
PSF	5,819	2,037	(3,782)
MRET	6,304	6,304	0
<b>Control total (incl PSF/MRET)</b>	<b>13,652</b>	<b>52</b>	<b>(13,600)</b>

# Finance Report

## APPENDIX 2 - ACTIVITY PERFORMANCE

	Year to date		
	Plan	Actual	Variance
Day case	30,682	30,073	(609)
Elective	5,340	4,745	(595)
Non-Elective	68,071	68,344	273
Outpatient	659,091	656,342	(2,749)
A&E	75,648	75,366	(282)
<b>Total</b>	<b>838,833</b>	<b>834,870</b>	<b>(3,963)</b>

(Note: the above exclude excess beddays)




## Finance Report


### APPENDIX 3 - CONTRACT AND OPERATING INCOME

<u>Contract Income by Point of Delivery</u>	<u>Year to date</u>		
	<u>Plan £'000</u>	<u>Actual £'000</u>	<u>Variance £'000</u>
Day case	23,108	22,783	(325)
Elective	18,164	17,506	(658)
Non-Elective	124,750	124,985	235
Outpatient	76,997	76,814	(183)
A&E	13,083	13,241	158
High Cost Drugs	38,518	37,458	(1,060)
Other	19,274	19,199	(75)
<b>Total</b>	<b>313,894</b>	<b>311,986</b>	<b>(1,908)</b>

<u>Contract Income by Commissioner</u>	<u>Year to date</u>		
	<u>Plan £'000</u>	<u>Actual £'000</u>	<u>Variance £'000</u>
BANES	94,005	95,659	1,654
Wiltshire	104,705	104,963	258
Somerset	35,717	34,794	(923)
Specialist Commissioners	47,187	47,004	(183)
BNSSG	13,642	12,910	(732)
Other NHSE	6,700	8,615	1,915
Other	11,938	8,041	(3,897)
<b>Total</b>	<b>313,894</b>	<b>311,986</b>	<b>(1,908)</b>




<u>Operating Income</u>	<u>Year to date</u>		
	<u>Plan £'000</u>	<u>Actual £'000</u>	<u>Variance £'000</u>
Other Patient Care	2,036	2,442	406
Provider to Provider	3,862	15,749	11,887
Education and Training	12,690	13,133	443
Donated Income	2,525	1,278	(1,247)
PSF	5,819	2,037	(3,782)
MRET	6,304	6,304	0
Other	17,352	18,821	1,469
<b>Total</b>	<b>50,588</b>	<b>59,764</b>	<b>9,176</b>



# Finance Report

## APPENDIX 4 - QIPP DELIVERY

	Year to date		
	Plan £'000	Actual £'000	Variance £'000
Medicine	4,500	3,080	(1,420)
Surgery	3,500	3,557	57
W&C	1,600	1,687	87
E&F	750	701	(49)
Corporate	1,050	1,109	59
Trustwide	1,500	622	(878)
<b>Total</b>	<b>12,900</b>	<b>10,756</b>	<b>(2,145)</b>



## Finance Report

### APPENDIX 5 - CAPITAL PROGRAMME EXPENDITURE

		Year to date	
	Plan	Actual	Variance
Source of Funds	£000s	£000s	£000s
Depreciation	12,599	12,263	(336)
Loan Repayments	(2,958)	(2,958)	0
Charitable Funds	2,825	827	(1,998)
Donations	0	451	451
Cash reserves/Other	22,085	17,402	(4,683)
	<b>34,552</b>	<b>27,985</b>	<b>(6,566)</b>
<b>Application of Funds</b>			
Medical Equipment (donated)	500	453	(47)
Strategic Capital (donated)	2,325	826	(1,499)
Ward upgrades	2,941	2,991	50
Other Estates projects	2,823	2,802	(20)
Clinical Systems	2,241	982	(1,259)
Other IM&T	3,906	1,263	(2,643)
Medical Equipment	4,926	4,042	(883)
RNHRD & Therapies build	2,556	3,016	461
Cancer Centre	5,003	3,963	(1,040)
Other Redevelopment works	7,270	6,556	(714)
COVID-19 Schemes	62	1,092	1,030
	<b>34,552</b>	<b>27,985</b>	<b>(6,566)</b>

Major Schemes - Whole Scheme Costs			
	FBC / OBC	Forecast	
	Refresh	Outturn	Variance
	£000s	£000s	£000s
RNHRD & Therapies Build	19,520	20,192	672
BCPS & Patient Accommodation	2,820	4,460	1,640
R&D Offices	900	1,495	595
Clinical Measurement	78	179	101
RNHRD Decommissioning	300	305	5
Oral Surgery & Orthodontics	2,670	3,195	525
Cancer Centre	43,600	50,593	6,993
North Decant & Demolitions	3,750	3,830	80
Temporary (Decant) Ward	1,450	2,252	802
Ward Upgrade - SAU	1,786	1,793	7

# Finance Report


## APPENDIX 6 - STATEMENT OF FINANCIAL POSITION

	<u>Plan £'000</u>	<u>Year to date Actual £'000</u>	<u>Variance £'000</u>
<b>Non current assets</b>			
Intangible assets	9,939	9,447	(492)
Property, Plant & Equipment	217,485	206,210	(11,275)
Trade and other receivables	1,182	1,567	385
<b>Non current assets total</b>	<b>228,606</b>	<b>217,224</b>	<b>(11,382)</b>
<b>Current Assets</b>			
Inventories	3,000	4,249	1,249
Trade and other receivables	31,684	22,569	(9,115)
Cash and cash equivalents	13,154	13,511	357
<b>Current Assets total</b>	<b>47,838</b>	<b>40,329</b>	<b>(7,509)</b>
<b>Current Liabilities</b>			
Trade and other payables	(28,387)	(30,745)	(2,358)
Other liabilities	(5,691)	(5,328)	363
Provisions	(335)	(214)	121
Borrowings	(3,424)	(3,441)	(17)
<b>Current Liabilities total</b>	<b>(37,837)</b>	<b>(39,728)</b>	<b>1,277</b>
<b>Total assets less current liabilities</b>	<b>238,607</b>	<b>217,825</b>	<b>(20,782)</b>
<b>Non current liabilities</b>			
Provisions	(763)	(1,092)	(329)
Borrowings	(10,813)	(10,925)	(112)
<b>TOTAL ASSETS EMPLOYED</b>	<b>227,031</b>	<b>205,808</b>	<b>(21,223)</b>
<b>Financed by:</b>			
Public Dividend Capital	160,790	161,211	421
Income and Expenditure Reserve	21,640	4,247	(17,393)
Revaluation reserve	44,601	40,350	(4,251)
<b>Total Equity</b>	<b>227,031</b>	<b>205,808</b>	<b>(21,223)</b>

# Finance Report

## APPENDIX 7 - STATEMENT OF CASHFLOWS

	Plan £'000	Year to Date Actual £'000	Variance £'000
Operating Surplus/(deficit)	19,119	(2,686)	(21,805)
Depreciation & Amortisation	12,600	12,264	(336)
Working Capital movement	2,950	22,780	19,830
Provisions	(3)	208	211
<b>Cashflow from/(used in) operations</b>	<b>34,666</b>	<b>32,566</b>	<b>(2,100)</b>
Capital Expenditure	(32,708)	(30,446)	2,262
Cash receipts from asset sales	0	23	23
<b>Cashflow before financing</b>	<b>(32,708)</b>	<b>(30,423)</b>	<b>2,285</b>
Public dividend capital received	1,720	2,142	422
Movement in loans from the DHSC	(2,958)	(2,958)	0
Capital element of finance lease rental payments	0	(443)	(443)
Interest received	100	179	79
Interest paid	(247)	(218)	29
Interest element of finance lease	(33)	(26)	7
PDC dividend (paid)/refunded	(6,332)	(6,260)	72
<b>Net cash generated from/(used in) financing activities</b>	<b>(7,750)</b>	<b>(7,584)</b>	<b>166</b>
<b>Increase/(decrease) in cash and cash equivalents</b>	<b>(5,792)</b>	<b>(5,441)</b>	<b>351</b>
<b>Opening Cash balance</b>	<b>18,946</b>	<b>18,946</b>	<b>0</b>
<b>Closing cash balance</b>	<b>13,154</b>	<b>13,505</b>	<b>351</b>



# Finance Report

## APPENDIX 8 - SINGLE OVERSIGHT FRAMEWORK

	Year to date			
	Plan Metric	Actual Metric	Plan Rating	Actual Rating
Capital Service Capacity	3.348	1.910	1	2
Liquidity	7.764	-3.791	1	2
I&E Margin	3.8%	0.0%	1	2
Distance from Financial Plan	0.0%	-3.8%	1	4
Agency Spend	-10.0%	44.0%	1	3
2019/20 Finance Rating	No trigger	Trigger	1	3

# Finance Report

## APPENDIX 10 - LOCAL HEALTH ECONOMY MONTH 11 PERFORMANCE

Organisation	Planned Outturn £'000	Likely Outturn £'000	Variance from Plan £'000	Planned YTD Outturn at Month 11 £'000	Actual YTD Outturn at Month 11 £'000	Variance from YTD Plan at Month 11 £'000
BaNES CCG	0	0	0	0	0	0
Swindon CCG	0	0	0	0	0	0
Wiltshire CCG	0	0	0	0	0	0
<b>Total CCGs</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
Avon and Wiltshire MH Partnership @ 45%	(2,262)	(4,625)	(2,363)	(2,068)	(3,515)	(1,447)
Great Western Hospitals FT	(6,770)	(15,624)	(8,854)	(6,503)	(15,080)	(8,577)
Royal United Hospitals FT	7,832	(1,909)	(9,741)	5,475	(3,232)	(8,707)
Salisbury NHS FT	(6,772)	(12,905)	(6,133)	(7,166)	(11,814)	(4,648)
<b>Total Providers</b>	<b>(7,972)</b>	<b>(35,063)</b>	<b>(27,091)</b>	<b>(10,262)</b>	<b>(33,641)</b>	<b>(23,379)</b>
<b>Total NHS</b>	<b>(7,972)</b>	<b>(35,063)</b>	<b>(27,091)</b>	<b>(10,262)</b>	<b>(33,641)</b>	<b>(23,379)</b>
B&NES Adult Social Care	0	0	0	0	0	0
Swindon Adult Social Care	0	(737)	(737)	0	0	0
Wiltshire Adult Social Care	0	(2,736)	(2,736)	0	(2,508)	(2,508)
<b>Total Adult Social Care</b>	<b>0</b>	<b>(3,473)</b>	<b>(3,473)</b>	<b>0</b>	<b>(2,508)</b>	<b>(2,508)</b>
<b>Total Health &amp; Adult Social Care</b>	<b>(7,972)</b>	<b>(38,536)</b>	<b>(30,564)</b>	<b>(10,262)</b>	<b>(36,149)</b>	<b>(25,887)</b>